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Abstract 
 
The common human epilepsies are associated with distinct patterns of reduced cortical 
thickness, detectable on neuroimaging, with important clinical consequences. To explore 
underlying mechanisms, we layered MRI-based cortical structural maps from a large-scale 
epilepsy neuroimaging study onto highly spatially-resolved human brain gene expression 
data, identifying >2,500 genes overexpressed in regions of reduced cortical thickness, 
compared to relatively-protected regions. The resulting set of differentially-expressed genes 
shows enrichment for microglial markers, and in particular, activated microglial states. 
Parallel analyses of cell-specific eQTLs show enrichment in human genetic signatures of 
epilepsy severity, but not epilepsy causation. Post mortem brain tissue from humans with 
epilepsy shows excess activated microglia. In an experimental model, depletion of activated 
microglia prevents cortical thinning, but not the development of chronic seizures. These 
convergent data strongly implicate activated microglia in cortical thinning, representing a 
new dimension for concern and disease modification in the epilepsies, potentially distinct 
from seizure control. 
 
  
 
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/470518doi: bioRxiv preprint first posted online Nov. 14, 2018; 
 7
Introduction 
 
Significant progress is being made in understanding disease processes in the epilepsies. 
Many genetic variants causing or associated with rare and common epilepsies have been 
reported1,2, with discovery continuing apace3. Numerous direct structural causes of epilepsy 
have been revealed by brain magnetic resonance imaging (MRI), since its widespread 
implementation in the period immediately preceding the extensive application of genetics. 
Several structural abnormalities are now themselves known to have a genetic basis4. As a 
result, the proportion of causally-explicable epilepsies is growing rapidly. Conversely, the 
mechanisms whereby these identified causes promote epileptogenesis and seizures remain 
obscure for most human epilepsies. Moreover, beyond causation and epileptogenesis, the 
epilepsies involve many other processes: some lead to clinically-apparent consequences, 
such as developmental delay or memory dysfunction, whereas others, without necessarily 
obvious symptoms, may be detected only on investigation - cerebellar atrophy is one 
example. The natural history of any given epilepsy need not be a single linear dynamic from 
causation to a unique, predictable, final outcome: for example, the epilepsies are associated 
with shortened longevity (even if seizures stop)5 and increased risk of particular 
comorbidities6. Known causes per se may not explain all the observed outcomes, suggesting 
that many epilepsies could be conceptualised as intricate matrices of causation, processes 
and outcomes7, with complex inter-dependencies, such as a likely link between reduction in 
cortical thickness and disease duration8.  
 
Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of 
common human epilepsies, which are known to have both distinct and shared genetic 
architecture2,3,9,10, there are also shared, pan-syndrome, and distinct, syndrome-specific, 
regional patterns of altered cortical thickness and altered subcortical grey matter volumes8. 
The causes of the structural changes in these epilepsies are not known. The findings 
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suggest structural losses may reflect an initial insult, subsequent epileptogenesis or 
progressive neurodegeneration, or some combination, and indicate that the epilepsies 
cannot necessarily be considered entirely benign at the structural level. We sought to identify 
processes underlying the structural findings.    
 
Human neurological disease biology has been successfully revealed using powerful 
combinations of brain MRI findings, regionalised brain-specific gene expression and gene 
co-expression network datasets, in systems biology approaches implicating candidate 
genes11–19. Here, we used the findings from the ENIGMA-Epilepsy study to direct 
interrogation for regionalised gene expression changes, which in turn identified candidate 
genes which might underlie thickness or volume reductions across the studied epilepsy 
syndromes. Gene expression is itself largely driven by underlying constitutional genetic 
variation. We therefore hypothesised that this approach could pick out disease mechanisms 
causing the observed structural changes. We then tested whether the postulated 
mechanisms were identifiable from epilepsy susceptibility or treatment-response genome-
wide association studies and further explored the findings with a series of additional 
experiments in both human and animal tissues. We demonstrate experimentally that 
depletion of the cell type, microglia, most strongly implicated by the systems biology 
approach can successfully avert cortical thinning. Together, the results point to the potential 
for prevention of the widespread, but largely unstudied, reduction in cortical thickness that 
accompanies common human epilepsies.  
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Results 
 
Cortical regions at most risk of reduced thickness in individuals with 
common forms of epilepsy are characterised by higher expression of 
over 2500 genes 
Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of 
common epilepsies, there are distinctive regional patterns of altered cortical thickness and 
altered subcortical grey matter volumes8. To identify the molecular basis of this regional 
vulnerability in the broad spectrum of epilepsies, we focused our analyses on the shared 
pan-syndrome cortical findings and leveraged data from the Allen Institute for Brain Science 
(AIBS) healthy human brain gene expression atlas (Figure 1). We chose to study all the 
epilepsies as a group not only because of the general importance of pan-syndrome cortical 
findings, but because these structural changes were most likely to reveal the condition-
specific, as opposed to syndrome-specific, processes driving the selective vulnerability of 
cortical regions. We hypothesised that matching patterns of regional cortical vulnerability to 
reduced thickness with patterns of gene expression differences across the human cortex 
would point to possible mechanisms underlying the brain structural changes, and then tested 
the emerging putative mechanisms in an experimental model.  
 
The AIBS healthy human brain gene expression atlas provided gene expression profiles for 
all cortical regions of interest. This gene expression atlas is unique in that from 158 to 348 
different brain structures have been sampled from each individual (n=6) covering in total 414 
different structures, and that sampling has been precisely mapped to MNI space, enabling 
linkage of the expression data to external brain maps in MNI space. Thus, the gene 
expression profiles used in this analysis were highly regionally specified. Of the 34 cortical 
regions profiled within the ENIGMA-Epilepsy data set, 11 were considered vulnerable to 
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reduced cortical thickness while 23 were considered relatively protected8. We compared 
these two types of cortical regions for significant differences in gene expression and 
identified 3,258 genes at the chosen P-value threshold (Supplementary Table 1). 
Interestingly, this gene list was dominated by the over-expression of genes within vulnerable 
regions (77.3%), with only 22.7% of the genes identified being more highly expressed in 
relatively protected cortical regions. Eleven genes (ATXN7L1, C12orf5, LDLRAD4, LRPAP1, 
NTM, RBBP4, SH3PXD2A, SLC44A5, SPECC1, UBE3C, ZNF81) had isoforms that were 
both over- and underexpressed. Considered together, these findings suggest that 
vulnerability to epilepsy-related reduced cortical thickness is primarily driven by specific 
regional risk factors, rather than the relative absence of protective factors. 
 
Genes associated with reduced cortical thickness in the common 
epilepsies are significantly enriched for microglial markers 
Although all cortical regions are similar in structure and cellular composition, there are 
regional differences, which are detectable within bulk gene expression data20–23. We 
determined whether the genes differentially expressed in vulnerable, as compared to 
relatively protected, cortical regions could be used to infer cell type(s) involved in mediating 
cortical thinning (Figure 1). First, we made use of cell-specific gene expression data 
generated using bulk mouse cortex, and covering the major cellular classes, namely 
astrocytes, endothelial cells, microglia, myelinating oligodendrocytes, newly-formed 
oligodendrocytes, oligodendrocyte precursor cells and neurons24. We used murine data 
initially, because of its more robust nature, unconfounded by disease effects. Using this 
approach, we identified a significant enrichment of sets of microglial-marking genes amongst 
those genes overexpressed in vulnerable cortex (PFDR=1.01x10-26; Supplementary Table 2). 
Conversely, those genes overexpressed in relatively protected cortical regions were 
enriched for sets of neuron-specific genes (PFDR=2.34x10-6; Supplementary Table 3). The 
availability of comprehensive, mouse brain single-cell RNA sequencing data25 allowed us to 
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investigate these findings further. Using these independently-derived data, we confirmed the 
significant enrichment of sets of microglial-marking genes, as well as genes enriched within 
perivascular macrophages and myocilin-expressing astrocytes, amongst those 
overexpressed in vulnerable cortex (Figure 2, Supplementary Table 4). In contrast, genes 
overexpressed in relatively protected cortical regions were strikingly enriched for gene sets 
specific to Vglut1-positive excitatory neurons (Figure 2, Supplementary Table 4). 
 
Since evidence suggests species differences in cell-specific expression26, we extended 
these findings using human-derived data26. Although these human data are more prone to 
confounding errors due to the small number of tissue samples used and the fact that cortex 
samples were obtained from surgical resections for a range of brain diseases including 
epilepsy (18 of 22), we were able to confidently replicate our major findings. In relatively 
protected areas, we confirmed enrichment of a neuron marker gene set derived from human 
tissue (PFDR=2.77x10-43; Supplementary Table 3). We also identified a highly significant 
enrichment of microglia-marking genes amongst those overexpressed in vulnerable cortical 
regions (PFDR=6.82x10-54; Supplementary Table 2). Together, these analyses from mouse 
and human data suggest that vulnerability to reduced cortical thickness is likely to be 
mediated at least partly through microglia-specific processes.  
 
Evidence for selected processes and microglial signatures amongst 
genes associated with reduced cortical thickness in the common 
epilepsies 
Moving beyond individual genes and cell types, we next investigated the biological 
processes that could underpin regional differences in vulnerability to reduced cortical 
thickness in epilepsy. In the first instance we investigated differentially expressed genes for 
evidence of Gene Ontology, KEGG and REACTOME pathway enrichment. Amongst genes 
overexpressed in relatively protected cortical regions, the most significant terms we identified 
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related to synaptic function (GO: Synapse, PFDR=1.60x10-7; GO: Neuronal postsynaptic 
density, PFDR=7.27x10-5; Supplementary Table 5). Conversely, amongst genes 
overexpressed in vulnerable cortical regions, the most significant terms related to immune 
function and regulation (GO: Immune system process, PFDR=6.68x10-14; GO: Positive 
regulation of immune system process, PFDR=2.16x10-13; Supplementary Table 6), consistent 
with our results derived using cell-specific gene sets. However, this approach also enabled 
us to obtain more specific process-related information and suggested the importance of the 
interferon gamma signalling pathway (GO: Cellular response to interferon gamma, 
PFDR=4.80x10-8; GO: Response to interferon gamma, PFDR=9.08x10-8; Supplementary Table 
6).  
 
Since microglia can exist in a range of activation states within the context of epilepsy27, we 
sought to integrate the cell-specific and pathway analyses already performed, to identify the 
microglial cell states of greatest importance in reduced cortical thickness. We collated gene 
signatures for distinct microglial states from the existing literature and also inferred 
signatures of microglial state through co-expression network analyses (see Online Methods). 
While there were significant overlaps in gene membership across the 16 microglial 
signatures used (Supplementary Figure 1), each of the gene lists were distinct. We identified 
a significant enrichment for 10 of the 16 signatures with genes overexpressed in vulnerable 
cortex. This included the microglial signature generated by Srivastava and colleagues28, 
which was positively correlated with seizure frequency in a mouse model of chronic epilepsy 
(PFDR=4.81x10-17; Supplementary Table 6). Striking enrichments were also identified for an 
inferred human microglial signature enriched for type 1-like microglial markers 
(PFDR=2.53x10-42; grey60; Supplementary Table 6), as well as signatures for aged, late 
activation, and de-activated microglia. However, we saw little evidence for enrichment within 
signatures of early activation (“Early Response” signature29, PFDR=4.53x10-1). Given that 
these enrichment results are ultimately derived from humans with an average duration of 
epilepsy of 17.42 (+/-11.99) years, the results suggest that the microglial states contributing 
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to reduced cortical thickness in epilepsy of this duration are shared with those microglial 
states recently implicated in various forms of chronic neurodegeneration29–31. However, the 
data do not exclude contributions from other microglial states at early stages of epilepsy in 
humans, including during epileptogenesis.  
 
Genetic evidence in support of immune activation as a modifying, but 
not causal, factor in common epilepsies 
Region-specific reduced cortical thickness across the common epilepsies was correlated 
with disease duration and age of onset of epilepsy8. Given that the analyses described 
above suggest the importance of microglia responses in vulnerability to reduced cortical 
thickness, we predicted that genetic variants affecting microglial responses would also 
impact upon the severity of epilepsy. While no microglial eQTL data set exists to date, eQTL 
analyses have been performed using monocytes at rest, and also monocytes treated with 
IFN-γ or lipopolysaccharide (LPS)32. We postulated that these eQTLs would be enriched for 
heritability of risk loci for epilepsy that is drug-resistant (one surrogate for disease severity) 
but not for epilepsy per se. To investigate this, we used GWAS data on epilepsy 
susceptibility2 and separate GWAS data on the phenotype of drug-resistant epilepsy from 
the EpiPGX consortium (www.epipgx.eu). Using LD score regression, we sought enrichment 
in heritability for these phenotypes within state-specific monocyte eQTLs32. We found no 
significant enrichment in the heritability of epilepsy in this form of annotation, suggesting that 
susceptibility to common epilepsies is less likely to be driven by immune processes (Table 
1). However, eQTLs regulating the response to IFN-γ were highly enriched for drug-resistant 
epilepsy vs drug-responsive epilepsy loci (P=0.00045; PFDR=0.0095, Table 1). This result 
was particularly striking given the small size of this GWAS (2423 drug-resistant cases vs 
1626 drug-responsive cases). Thus, we provide genetic evidence in support of microglial-
mediated responses as a modifying factor in severity of epilepsy, but not its susceptibility. 
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Widespread regionalised over-representation of microglia in human 
brain tissue from people with epilepsy 
Based on the analyses above, we predicted that brain tissue from individuals with various 
forms of epilepsy would have regionalized higher densities of microglia as compared to 
tissue from non-epilepsy controls and that this would be apparent beyond the context of 
acute seizure activity. In order to test this hypothesis, we investigated microglia density 
across 14 regions of interest (ROIs) in post mortem brain tissue derived from 55 individuals, 
including individuals with non-lesional epilepsy (EP-NL, n=18), lesional epilepsy (EP-L, 
n=21) and non-epilepsy controls (NEC, n=16). Using Iba-1 immunolabelling, we found that 
single ramified microglia and processes were found throughout the cortex; scattered 
perivascular macrophages were also labelled (Figure 3a). Enlarged and more 
complex/branching microglia, focal aggregates and amoeboid/macrophage forms were 
noted in some ROIs (Figure 3a). Consistent with our hypothesis, the Iba1 labelling index was 
significantly higher in all epilepsy (EP-NL and EP-L together) than NEC for all ROIs 
(P=4.0x10-13) and for both subgroup comparisons (EP-NL [P=3.7x10-13] and EP-L 
[P=3.5x1013]) against NEC. Regional differences were noted within the epilepsy groups, and 
for individual ROIs compared between epilepsy and control groups (see Figure 3 and 
Supplementary Table 7). Whilst we did not attempt to formally map histopathological ROIs to 
the ENIGMA-Epilepsy ROIs because of tissue processing-related artefacts, we noted that 
the Iba1 labelling index was similar across EP-NL, EP-L and NEC in BA17, as compared to 
pulvinar and BA22 where the Iba1 labelling index was higher in EP-NL and EP-L groups 
than in NEC. Thus, these results are consistent with the view that there is an over-
representation of microglia in brain tissue from people with chronic epilepsy, and that such 
microglial responses may occur in a regionally-specific manner. 
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Experimental evidence in support of microglial activation as a modifying 
factor for cortical thickness in a mouse model of epilepsy 
To provide proof-of-concept evidence causally linking microglia activation to cortical thinning, 
we used a mouse model of acquired epilepsy where convulsive seizures originate and 
spread in the limbic system, and also involve the neocortex.33–36 This model mimics features 
of mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE), with neuronal damage 
also observed in extrahippocampal areas33,34,36, as also shown in human MTLE in the 
ENIGMA-Epilepsy study8. Spontaneous seizures are triggered by status epilepticus (SE) 
evoked in the amygdala. Spontaneous seizures develop after a latent phase after the 
primary insult (onset, 6.2±0.5 days, n=21) and recur for months (Supplementary Figure 2), 
and are drug-resistant34. Microglia are morphologically activated and proliferate by 3-fold on 
average within one week after SE as assessed in a different cohort of mice by analysis of 
Iba-1-positive cells in the forebrain (number of cells, hippocampus: sham, 1013±129; 1 week 
post-SE, 2837±250, P=0.0001, n=10-11 mice).  
First, we studied whether the thickness and volume of selected cortical brain regions were 
reduced, and those of the lateral ventricles increased (directions of change as predicted by 
the ENIGMA-Epilepsy findings in humans) in placebo-diet fed epileptic mice (n=10) vs sham 
mice (not exposed to SE, n=8) as assessed by post mortem MRI. We found that the lateral 
ventricles were enlarged by 2-fold (P=0.0004, one-tailed t-test): this effect was associated 
with an average 10% significant reduction in the volume of the hippocampus (P=0.0043) and 
entorhinal cortex (P=0.0061), and caudato-putamen (P=0.049) (Supplementary Figure 3). 
No significant changes were observed in other brain areas such as the thalamus and the 
perirhinal cortex, although the average volumes of both were lower than the corresponding 
values in sham mice (Supplementary Figure 3). Notably, a significant reduction in the 
thickness of both entorhinal (P=0.0001; Figure 4a) and perirhinal cortices (P=0.0338; 
Supplementary Figure 4) was also measured in the same mice. 
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Next, we measured brain region volumes and cortical thickness in mice treated with 
PLX3397. The drug was administered via food to massively reduce the number of microglial 
cells in the forebrain during the post-insult epileptogenesis phase (prodromal to epilepsy 
onset) and in the early phase after spontaneous seizures begin. Importantly, this decrease 
was induced transiently in order to assess the impact of microglia activation in the initial 
phases of the disease on the structural brain changes we detected in the epileptic mice. We 
found that the thickness of the entorhinal cortex of microglia-depleted mice was similar to 
sham mice, thus indicating that microglia depletion prevented the cortical thinning of this 
ictogenic brain area in epileptic mice (P=0.0068 vs placebo; Figure 4a). Microglia depletion 
did not affect the thinning of the perirhinal cortex (Supplementary Figure 4) or any of the 
brain volume changes occurring in epileptic mice (Supplementary Figure 3). Evaluation of 
neuronal cell numbers in the entorhinal cortex showed a 14% decrease in cell density 
(P=0.0487 vs sham; Figure 4b) and in their average cell body size (P=0.01 vs sham; Figure 
4b) in the epileptic mice receiving placebo diet. The reduction in cell density was prevented 
in epileptic mice when microglia had been depleted during epileptogenesis by PLX3397 
(P=0.02 vs placebo; Figure 4b). 
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Discussion 
 
The epilepsies are complex conditions with multiple facets including various causes, differing 
responses to treatment, and unpredictable outcomes. Most attention has been paid to 
causation and processes of epileptogenesis across the broad constituent spectrum of 
syndromes. In contrast, disease progression has not been a primary focus of research even 
though for some rare epilepsies (the developmental and epileptic encephalopathies, DEE), 
the window of opportunity to ameliorate disease may be open for longer than expected, as 
disrupted patterns of gene expression last into adulthood18. Here, we show that across the 
broad spectrum of the more common epilepsies (specifically excluding DEE), patterns of 
gene expression spatially correlated with reduced cortical thickness implicate 
neuroinflammatory processes, and, particularly, microglial activation, as contributors to the 
underlying cause of reduction in cortical thickness. We show that this molecular signature of 
neuroinflammation significantly overlaps with a gene set already causally linked to seizure 
frequency in a mouse model of chronic epilepsy28. Further, our data add new evidence 
showing that microglial activation is associated with at least some of the structural changes 
seen in brain areas involved in seizure circuitry, in that microglial depletion can directly 
prevent associated cortical thinning.  
 
We tested the hypothesis that microglial/monocyte activation is a key modulator of the 
severity of epilepsy using both genetic and functional approaches. We used the availability 
of GWAS data for resistance to anti-epileptic drug treatment, a marker of disease severity, to 
investigate enrichment in heritability at genetic loci already known to influence the 
expression of genes involved in monocyte activation. We note this analysis assumes a high 
degree of similarity in the genetics of gene expression in monocytes and microglia. We find a 
highly significant enrichment in the heritability of epilepsy severity amongst these 
immunomodulatory loci, despite the absence of a significant enrichment for heritability of 
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epilepsy per se. Finally, in keeping with these observations, experimental microglial 
depletion timed to coincide with a period of epileptogenesis in a murine model can prevent 
regionalised cortical thinning, but does not influence the eventual development of seizures 
themselves in our model. Data from the experimental model also demonstrate that the 
cortical thinning is at least partly due to reduced neuronal cell density and average neuronal 
size: reduction of neuronal density can be prevented by appropriately-timed microglial 
depletion (neuronal size changes were not rescued, which may explain the observation that 
entorhinal volume changes are not completely prevented by microglial depletion). We, and 
others37–41, find activated, Iba1+-microglia are present in excess in brain tissue from people 
with epilepsy, compared to brain tissue from healthy controls, providing evidence for 
translation to human epilepsies of our assertions from the experimental model data. 
Together, these findings separate important processes occurring in the course of the 
epilepsies, and incriminate potentially modifiable microglial activation states in the hitherto 
largely-ignored feature of cortical thinning in the common human epilepsies. Our results also 
suggest other factors are likely to be involved. 
 
Importantly, we note that the clue to the possible role for microglial activation in cortical 
thinning came from a cross-sectional study of chronic human epilepsy: although reduced 
cortical thickness correlated with disease duration8, we could not distinguish whether the 
structural difference had developed at disease onset (e.g. with causation), during 
epileptogenesis, during the course of the disease, or a combination of these epochs. Our 
multimodal data, and especially the experimental model results, allow us to begin to address 
this question. The model relates to early processes in epileptogenesis, and show a 
separation for microglial roles in cortical thinning and seizure occurrence, whilst data from 
another model relates to the chronic disease state, and shows an effect of microglial 
manipulation on seizure frequency in that chronic state28 (cortical thinning was not assessed 
in that model). The models and data are not directly compatible, and we cannot test 
hypotheses arising from the chronic model in data from ENIGMA-Epilepsy. However, taken 
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together, the data suggest microglia may have multiple modifying roles during 
epileptogenesis and progression of disease across common human epilepsies, though we 
find no evidence that they contribute to the actual occurrence of these common forms of 
epilepsy (from either our human or murine data). That seizure frequency and cortical 
thinning may be separable processes adds to important epidemiological evidence that 
seizure frequency is not the only contributor to morbidity in people with a history of epilepsy.5 
Microglia are already known to have many roles in specific types of epilepsy, demonstrated 
clearly in a variety of animal models. Such roles include phagocytosis, which may link 
consumption of synapses with cognitive changes in long-term active epilepsy,42 providing 
another possible mechanism for actual loss of brain volume in epilepsy: ‘time is brain’43.  
 
Considering the complex relationship between inflammation and epilepsy, it is noteworthy 
that despite the growing evidence for neuroinflammation as a modulator of epilepsy, overt 
neuroinflammation is considered causal in a very few, rare, severe human epilepsies. 
Rasmussen’s encephalitis is a severe drug-resistant epilepsy characterised by progressive 
loss of cerebral substrate, in which astrogliosis and T-lymphocyte infiltration are central 
features, with IFN-γ and granzyme B overactivity and evidence of efficacy of α4 integrin 
blockade44. Microglial activation is also seen in Rasmussen’s encephalitis, and in tissue from 
epilepsies due to hippocampal sclerosis and mesial temporal lobe sclerosis, focal cortical 
dysplasia (FCD) and tuberous sclerosis37–41. The latter two conditions are known to have 
genetic, rather than inflammatory, causes, but the extent of microglial activation in the 
chronic disease phase correlates with seizure frequency and disease duration in these 
studies37,41, pointing again to distinction between processes related to the initial cause and 
others manifest during active disease. Importantly, resected human brain tissue is only 
available from a few cases of a few types of epilepsies (mostly surgical specimens from 
MTLE and FCD45), so that it is impossible to otherwise evaluate the role of microglia using 
neuropathological data in the majority of common human epilepsies, from which brain tissue 
cannot be obtained in life. Brain imaging in animal models using a label (TSPO) for 
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microglial activation shows dynamic upregulation during epileptogenesis, with persistent, 
although declining, activity in the chronic phase and correlation with spontaneous seizures46; 
in chronic human TLE, there is increased TSPO binding ipsilateral and contralateral to 
seizure foci47. Using immunolabelling, we demonstrate that there is over-representation of 
activated microglia in human and experimental brain tissue, compared to controls. However, 
neither TSPO imaging nor neuropathological study is realistically applicable to large 
numbers of people with epilepsy, whilst MRI is. We propose, using MRI-derived patterns and 
correlation with gene expression, that microglial-associated neuroinflammation drives the 
important, but as yet largely neglected, phenotype of cortical thinning in a broad swathe of 
common human epilepsies. Subsequent experimental intervention in an animal model 
suggests that early manipulation of microglia has the capacity to rescue disease-related 
cortical thinning, opening up new areas for attention and treatment in common human 
epilepsies.   
 
Our results point to important roles for neuroinflammation and potentially specific molecular 
actors, such as IFN-γ. However, the diversity of microglial states and functions, and the 
complex, dynamic, interactions between neurons, astroglia and microglia, that at the very 
least can promote epileptogenesis27 have yet to be fully resolved. Our key observation is that 
microglial activation is not a rare phenomenon in the epilepsies, but is likely to be central 
across the breadth of types of epilepsy. Not only does this deepen understanding and show 
that some disease processes and progression in epilepsy may be independent of cause, but 
also offers new avenues for treatment and disease modification. Manipulation of microglial 
activity may not only address the common phenomenon of treatment resistance28, but may 
also prevent irreversible loss of brain substance.  
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Figures 
Figure 1. Analysis overview 
Panel a: Cortical samples of the AIBS dataset were marked as “vulnerable” or “relatively 
protected” based on whether they were located in a brain region that showed significant 
reduction in cortical thickness or not, respectively, in a large imaging study8. Differential 
gene expression analysis between the two groups produced the genetic risk signature of 
reduced cortical thickness in epilepsy.  
Panel b: Significantly differently expressed genes with higher expression in “vulnerable” 
regions were found to be enriched for marker genes for microglia as well as immune 
activation related pathways.  
Panel c: LD score regression estimating the enrichment of immune response eQTL 
signatures in different epilepsy GWAS finds strong enrichment in disease severity (drug-
resistant vs drug-susceptible) but not in disease risk (cases vs controls). 
 
Figure 2. Cell type-specific enrichments amongst genes overexpressed in “vulnerable” 
and “relatively protected” cortical regions 
Using EWCE, genes passing an FDR<0.01 with a negative or positive t-statistic, (namely 
genes more highly expressed in “vulnerable” as opposed to “relatively protected” cortical 
regions respectively) were tested for their enrichment in various CNS-associated neuronal 
and glial clusters identified by Zeisel et al25 in a murine single-cell dataset. Displayed here 
are all clusters whose origin is within cortical regions (amounting to 43 of the 127 clusters 
tested in total). Neuronal clusters are coloured by their associated neurotransmitter, as 
determined by Zeisel et al. using expression of genes coding for neurotransmitter 
transporters or enzymes crucial to their synthesis. Standard deviations from the mean 
indicate the distance of the mean expression of the target list from the mean expression of 
the bootstrap replicates. Asterisks denote significance at PFDR<0.05 after correcting for 
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multiple testing with the FDR method over all gene sets and cell types displayed. For a full 
list of all clusters, gene sets, and numerical results see Supplementary Table 4. 
 
Figure 3. Presence of excess activated microglia in post mortem brain tissue from 
people with epilepsy 
Panel a: Top row: Iba1 labelling randomly selected from cases in the study (representing all 
three groups) with a range of staining from 0.5 to 6.5% with progressive increase in 
complexity, number and size of ramified microglial (all taken at x20). Bottom row: High 
magnification of morphological types of Iba1-labelled cells including (left to right) ‘rod’ cells, 
ramified microglia, perivascular macrophage and amoeboid forms. Fixation time in 
illustration of ramified microglia was 467 days (bar = 30 microns).   
 
Panel b: Scatter graph of all data points from 709 sections including all brain regions 
showing mean and standard deviation in the four main groups: Epilepsy-ALL (EP-ALL), 
Epilepsy Non-Lesional (EP-NL), Epilepsy-Lesional (EP-L) and non-epilepsy controls (NEC). 
EP-ALL, EP-NL, EP-L are all significantly greater than NEC (*respective P-values: 4.0x10-13, 
3.7x10-13, 3.5x10-13)  
 
Panel c. Iba1 immunolabelling shown in 10 Brodmann areas in each hemisphere colour 
coded for the mean percentage labelling in each group. THAL-M, medial thalamus, THAL-L, 
lateral thalamus, PULV, lateral pulvinar. 
 
Panel d. Scatter graph of the mean Iba1 immunolabelling in the same Brodmann areas 
including both hemispheres in the four groups listed above.  
 
Figure 4. Effects of PLX3397 on entorhinal cortex thickness in epileptic mice 
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Panel a: box-and-whisker plots depicting median, minimum, maximum and single values 
related to the quantification of entorhinal cortex thickness, as assessed by quantitative post-
mortem MRI performed at the end of EEG monitoring (placebo: n=10; PLX3397: n=7), and in 
sham mice (n=8). Mice studied with MRI were randomly selected from those described in 
Supplementary Figure 2. MRI images depict representative slices showing the ROI used to 
quantify the cortical thickness. The white line within the ROI was manually drawn to measure 
the cortical thickness. **P=0.0001 vs sham; #P=0.0068 vs placebo by one-tailed t test. Scale 
bar: 1 cm.  
 
Panel b: representative Nissl-stained sections of the entorhinal cortex in the experimental 
groups (top row), and the relative quantification of the number and the average size of Nissl-
stained neurons (bottom row). One sham mouse and two placebo mice were excluded from 
the analysis due to poor quality of Nissl staining.  Data are shown by box-and-whisker plots 
depicting median, minimum, maximum and single values *P=0.0487, **P=0.0103 vs sham; 
#P=0.02 vs placebo by one-tailed t test. Scale bars: 100 µm. 
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Figure 1 
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Figure 2 
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